Crescent Biopharma, Inc.

CBIO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$37,879-$36,899-$46,689-$63,427
Dep. & Amort.$35$153$207$265
Deferred Tax$0$0$0$2
Stock-Based Comp.$0$3,560$3,858$6,087
Change in WC$1,159-$2,559-$4,662-$1,165
Other Non-Cash$5,587$865$829$749
Operating Cash Flow-$31,098-$34,880-$46,457-$57,490
Investing Activities
PP&E Inv.-$10-$21-$84-$15
Net Acquisitions$30$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$20-$21-$84-$15
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$5$28,707$4,157$10,699
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$116$0$25
Financing Cash Flow$5$28,824$4,157$10,724
Forex Effect$0$0$0$0
Net Chg. in Cash-$31,073-$6,078-$42,384-$46,780
Supplemental Information
Beg. Cash$41,793$47,871$90,255$137,035
End Cash$10,720$41,793$47,871$90,255
Free Cash Flow-$31,108-$34,901-$46,542-$57,504